PCM
QTTB icon

Prelude Capital Management’s Q32 Bio QTTB Stock Holding History

Prelude Capital Management’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,133
Closed -$258K – 1553
2024
Q1 		$258K Buy
+15,133
New +$209K 0.01% 967
2021
Q3 		– Sell
-644
Closed -$84K – 2078
2021
Q2 		$84K Buy
+644
New +$80.4K ﹤0.01% 1492
2020
Q4 		– Sell
-6
Closed -$1K – 2094
2020
Q3 		$1K Buy
+6
New +$1.34K ﹤0.01% 1744
2019
Q3 		– Sell
-18
Closed -$6K – 2122
2019
Q2 		$6K Buy
+18
New +$7.07K ﹤0.01% 1510
2019
Q1 		– Sell
-232
Closed -$93K – 2263
2018
Q4 		$93K Buy
+232
New +$87.7K 0.01% 954

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Prelude Capital Management's QTTB Position: Q2 2024 in Review

Prelude Capital Management sold out of Q32 Bio (QTTB) in Q2 2024, closing a stake of 15,133 shares — an estimated $258K sold.

Prelude Capital Management first reported a position in QTTB in Q4 2018 and held it in 5 quarters. The position peaked at $258K in Q1 2024. 54 funds tracked by Wall St. Rank hold QTTB as of Q2 2024.

  • Prelude Capital Management reported no remaining Q32 Bio position as of Q2 2024 after selling out during the quarter.
  • Prelude Capital Management sold 15,133 Q32 Bio shares in Q2 2024, an estimated $258K.
  • Prelude Capital Management first reported a position in Q32 Bio in Q4 2018 and held it in 5 quarters.
  • Prelude Capital Management's Q32 Bio position peaked at $258K in Q1 2024.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2024.

Based on Prelude Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.